Treatment of in-stent restenosis (ISR) lesions with the XIENCE everolimus-eluting stent (EES) showed comparable stent expansion to treatment of non-ISR lesions but with a smaller minimal stent area and higher rates of target lesion failure (TLF), a new analysis of a randomized trial shows.